Uncategorized Archives - Eikon Therapeutics

Eikon Therapeutics Management to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

HAYWARD, Calif. — August 26, 2024 — Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery and development, today announced that CEO and Board…

Eikon Therapeutics to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

HAYWARD, Calif. – June 6, 2024 — Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery and development, today announced that CEO and Board…

Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

HAYWARD, Calif. – MAY 28, 2024 – Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery and development, announced today that multiple abstracts highlighting…

Eikon Therapeutics Presents Pharmacokinetic/Biomarker Analysis of the Toll-Like Receptor 7 and 8 (TLR7/8) Agonist EIK1001 at the Annual Meeting of the American Association for Cancer Research

In this poster presented at AACR, the research team describes findings from analyses of EIK1001 pharmacokinetics (PK) and cytokine biomarker data from two Phase 1 clinical trials in participants with…

Archive for Uncategorized

Eikon Therapeutics Management to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Eikon Therapeutics to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Eikon Therapeutics Presents Pharmacokinetic/Biomarker Analysis of the Toll-Like Receptor 7 and 8 (TLR7/8) Agonist EIK1001 at the Annual Meeting of the American Association for Cancer Research

Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference

Exclusive: Roger Perlmutter on the biggest problem in Big Pharma, leaving Merck, and building Eikon

Roger Perlmutter lights up the biological dark, building a new pharma force in Eikon and its superpowered microscopes

Eikon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Eikon Therapeutics Announces the Election of Robert L. Huffines to its Board of Directors

Eikon Therapeutics Announces Business Update Highlighting Pipeline and Clinical Development Progress